StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
10
Publishing Date
2022 - 06 - 07
1
2022 - 05 - 02
1
2022 - 03 - 16
1
2021 - 09 - 30
1
2021 - 09 - 09
1
2021 - 05 - 25
2
2021 - 03 - 17
2
2020 - 12 - 10
1
Sector
Consumer non-durables
1
Health technology
10
Manufacturing
1
Tags
Acquisition
1
Active
1
Alliances
1
Als
4
Application
4
Approval
4
Aspaveli
2
Biomidwest
2
Chmp
3
Clinical-trials-phase-iii
5
Collaboration
2
Companies
3
Company announcement
2
Conference
21
Corporation
5
Deadline
17
Drug
5
Earnings
5
Empaveli
4
Europe
2
Events
4
Fda
7
Financial
9
Financial results
6
Food
2
Genetown
3
Global
3
Grant
7
Granted
6
Grants
15
Growth
2
Health
3
J.p. morgan healthcare conference
2
Kidney
2
Market
2
Meeting
5
Money
2
N/a
146
Nasdaq
17
Offering
4
People
2
Pharmaceuticals
37
Phase 2
2
Phase 3
10
Positive
7
Presentation
2
Rare
3
Report
3
Research
7
Results
29
Retina
6
Review
3
Syfovre
8
Technology
3
Therapy
2
Topline
4
Treatment
13
Trusted
3
Update
2
Year
3
Entities
Apellis pharmaceuticals, inc.
10
Kering
1
Symbols
ABBV
30
ACHV
6
ADIL
11
ALBO
6
ALDX
11
ALNY
23
AMGN
7
APLS
10
ARQT
11
AVDL
7
AZN
7
BBI
12
BGNE
8
BHC
6
BHVN
8
BIIB
12
BMRN
8
BMY
12
BYSI
10
CHRS
13
CRNX
8
CTXR
9
CYTH
6
DVAX
11
EIGR
9
EXEL
10
GILD
9
HGEN
9
IDYA
8
IMAB
9
INCY
23
INO
8
IONS
9
JAZZ
7
JNJ
29
LLY
47
MDGL
8
MESO
9
MRK
18
MRNA
10
MYOV
11
NOVN
10
NVAX
13
NVCR
8
OCUP
8
ONTX
7
ORMP
7
PFE
21
REGN
26
SAVA
9
SCYX
12
SNY
44
SNYNF
26
SRNE
8
TAK
19
TEVJF
15
TGTX
18
TNXP
10
VERU
10
ZEAL
7
Exchanges
Nasdaq
10
Crawled Date
2022 - 06 - 07
1
2022 - 05 - 02
1
2022 - 03 - 16
1
2021 - 09 - 30
1
2021 - 09 - 09
1
2021 - 05 - 25
2
2021 - 03 - 18
1
2021 - 03 - 17
1
2020 - 12 - 10
1
Crawled Time
00:00
1
11:00
1
11:01
1
12:00
2
12:20
1
16:00
1
20:00
1
22:00
2
Source
www.biospace.com
4
www.globenewswire.com
5
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 3
symbols :
Apls
save search
Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Published:
2022-06-07
(Crawled : 12:20)
- biospace.com/
PPRUF
|
News
|
$364.27
37.56%
850
|
Consumer Non-Durables
|
-37.99%
|
O:
3.52%
H:
1.44%
C:
-2.89%
PPRUY
|
News
|
$36.96
-0.11%
220K
|
Manufacturing
|
-39.78%
|
O:
-1.18%
H:
1.95%
C:
1.75%
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
4.8%
|
O:
-7.87%
H:
5.53%
C:
5.37%
rare
kidney
phase 3
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Published:
2022-05-02
(Crawled : 20:00)
- globenewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
10.85%
|
O:
2.39%
H:
4.58%
C:
-0.87%
phase 3
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Published:
2022-03-16
(Crawled : 11:00)
- globenewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
21.65%
|
O:
2.3%
H:
14.33%
C:
10.42%
phase 3
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
Published:
2021-09-30
(Crawled : 16:00)
- globenewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
43.59%
|
O:
2.98%
H:
0.0%
C:
-5.67%
results
retina
phase 3
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
Published:
2021-09-09
(Crawled : 22:00)
- biospace.com/
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
-12.34%
|
O:
-0.88%
H:
2.83%
C:
0.94%
fda
results
phase 3
topline
fda ide
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Published:
2021-05-25
(Crawled : 12:00)
- biospace.com/
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
3.22%
|
O:
2.31%
H:
3.23%
C:
0.02%
treatment
positive
results
phase 3
topline
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Published:
2021-05-25
(Crawled : 12:00)
- biospace.com/
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
3.22%
|
O:
2.31%
H:
3.23%
C:
0.02%
treatment
positive
results
phase 3
topline
The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
Published:
2021-03-17
(Crawled : 00:00)
- prnewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
6.05%
|
O:
-0.09%
H:
3.29%
C:
-4.14%
results
phase 3
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
Published:
2021-03-17
(Crawled : 22:00)
- globenewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
6.05%
|
O:
-0.09%
H:
3.29%
C:
-4.14%
results
phase 3
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
Published:
2020-12-10
(Crawled : 11:01)
- globenewswire.com
APLS
G
|
$48.69
2.2%
2.16%
1.2M
|
Health Technology
|
-0.29%
|
O:
0.1%
H:
3.46%
C:
0.25%
positive
results
phase 3
topline
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.